Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults

Nat Immunol. 2024 Feb;25(2):316-329. doi: 10.1038/s41590-023-01717-5. Epub 2024 Jan 5.

Abstract

Pneumococcal infections cause serious illness and death among older adults. The capsular polysaccharide vaccine PPSV23 and conjugated alternative PCV13 can prevent these infections; yet, underlying immunological responses and baseline predictors remain unknown. We vaccinated 39 older adults (>60 years) with PPSV23 or PCV13 and observed comparable antibody responses (day 28) and plasmablast transcriptional responses (day 10); however, the baseline predictors were distinct. Analyses of baseline flow cytometry and bulk and single-cell RNA-sequencing data revealed a baseline phenotype specifically associated with weaker PCV13 responses, which was characterized by increased expression of cytotoxicity-associated genes, increased frequencies of CD16+ natural killer cells and interleukin-17-producing helper T cells and a decreased frequency of type 1 helper T cells. Men displayed this phenotype more robustly and mounted weaker PCV13 responses than women. Baseline expression levels of a distinct gene set predicted PPSV23 responses. This pneumococcal precision vaccinology study in older adults uncovered distinct baseline predictors that might transform vaccination strategies and initiate novel interventions.

MeSH terms

  • Aged
  • Antibodies, Bacterial*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Pneumococcal Vaccines
  • Polysaccharides
  • Streptococcus pneumoniae*
  • Vaccination
  • Vaccines, Conjugate

Substances

  • Vaccines, Conjugate
  • Antibodies, Bacterial
  • Pneumococcal Vaccines
  • Polysaccharides